These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 8046902

  • 1. [Some aspects of current treatment of patients with terminal chronic renal insufficiency].
    Burtsev VI, Grankin VI, Briukhovetskiĭ AG, Klopotskiĭ SA, Miasnikova EB.
    Klin Med (Mosk); 1993 Jan; 71(1):33-6. PubMed ID: 8046902
    [Abstract] [Full Text] [Related]

  • 2. [The efficacy of an erythropoietin-calcitriol combination in patients with chronic kidney failure on programmed hemodialysis].
    Nikolaev AIu, Klepikov PV, Lashutin SV, Kukhtevich AV.
    Ter Arkh; 1995 Jan; 67(5):27-31. PubMed ID: 7638771
    [Abstract] [Full Text] [Related]

  • 3. [The use of recombinant erythropoietin with patients on programmed hemodialysis].
    Rozental' RL, Zezina LIu, Spudass AV.
    Ter Arkh; 1991 Jan; 63(12):110-3. PubMed ID: 1803587
    [Abstract] [Full Text] [Related]

  • 4. Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.
    Khosroshahi HT, Shoja MM, Tubbs RS, Estakhri R, Ardalan MR.
    Transplant Proc; 2007 May; 39(4):1051-3. PubMed ID: 17524889
    [Abstract] [Full Text] [Related]

  • 5. Factors affecting survival in advanced chronic kidney disease patients who choose not to receive dialysis.
    Wong CF, McCarthy M, Howse ML, Williams PS.
    Ren Fail; 2007 May; 29(6):653-9. PubMed ID: 17763158
    [Abstract] [Full Text] [Related]

  • 6. [Transplantation of the kidney--optimal treatment of patients suffering from diabetes mellitus type 1 with terminal chronic renal failure].
    Shamaeva EN, Shestakova MV, Kim IG, Stoliarevich ES, Tomilina NA.
    Ter Arkh; 2007 May; 79(6):40-4. PubMed ID: 17684965
    [Abstract] [Full Text] [Related]

  • 7. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M, Popławski A, Kaliszewski Z, Juzwiuk J.
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [Abstract] [Full Text] [Related]

  • 8. Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. The Canadian Erythropoietin Study Group.
    Laupacis A.
    Semin Nephrol; 1990 Mar; 10(2 Suppl 1):11-9. PubMed ID: 2192412
    [No Abstract] [Full Text] [Related]

  • 9. Results of the Canadian morbidity study in end-stage renal disease patients treated by hemodialysis.
    Churchill DN.
    Semin Nephrol; 1990 Mar; 10(2 Suppl 1):66-72. PubMed ID: 2356368
    [No Abstract] [Full Text] [Related]

  • 10. [The effect of recombinant human erythropoietin during hemodialysis on the thrombocyte and erythrocyte functions of patients with chronic kidney failure].
    Rud'ko IA, Balashova TS, Kubatiev AA, Ermolenko VM.
    Ter Arkh; 1994 Mar; 66(6):57-60. PubMed ID: 7940371
    [Abstract] [Full Text] [Related]

  • 11. [Analysis of survival in dialysis: hemodialysis versus peritoneal dialysis and the significance of comorbidity].
    Antolín A, Miguel A, Pérez J, Gómez C, Zurriaga O, Blasco MJ, García R.
    Nefrologia; 2002 Mar; 22(3):253-61. PubMed ID: 12123125
    [Abstract] [Full Text] [Related]

  • 12. Preemptive living-donor renal transplantation: outcome and clinical advantages.
    Yoo SW, Kwon OJ, Kang CM.
    Transplant Proc; 2009 Mar; 41(1):117-20. PubMed ID: 19249492
    [Abstract] [Full Text] [Related]

  • 13. Long-term outcome of kidney transplantation in patients with hepatitis C virus infection.
    Huo TI, Yang WC, Wu JC, King KL, Lin CY, Loong CC, Lui WY, Chang FY, Lee SD.
    Hepatogastroenterology; 2001 Mar; 48(37):169-73. PubMed ID: 11268958
    [Abstract] [Full Text] [Related]

  • 14. [Epidemiology of end-stage renal disease before starting hemodialysis and factors influencing hemodialysis survival].
    Ben Hamida F, Karoui C, Abderrahim E, Smaoui W, Kaaroud H, Béji S, Barbouche S, Goucha R, Ben Abdallah T, Ben Moussa F, Ben Maiz H, Kheder A.
    Tunis Med; 2007 Mar; 85(3):230-3. PubMed ID: 17668580
    [Abstract] [Full Text] [Related]

  • 15. Survival on chronic dialysis: 10 years' experience of a single Colombian center.
    Enríquez J, Bastidas M, Mosquera M, Ceballos O, Bastidas B, Argote E, Salazar J, Delgado M.
    Adv Perit Dial; 2005 Mar; 21():164-7. PubMed ID: 16686311
    [Abstract] [Full Text] [Related]

  • 16. Among therapy modalities of end-stage renal disease, renal transplantation improves survival in patients with amyloidosis.
    Ozdemir BH, Ozdemir FN, Sezer S, Sar A, Haberal M.
    Transplant Proc; 2006 Mar; 38(2):432-4. PubMed ID: 16549140
    [Abstract] [Full Text] [Related]

  • 17. Duration of end-stage renal disease and kidney transplant outcome.
    Goldfarb-Rumyantzev A, Hurdle JF, Scandling J, Wang Z, Baird B, Barenbaum L, Cheung AK.
    Nephrol Dial Transplant; 2005 Jan; 20(1):167-75. PubMed ID: 15546892
    [Abstract] [Full Text] [Related]

  • 18. Outcome and survival in different peritoneal dialysis modalities.
    Al-Hilali N, Al-Humoud H, Nampoory M, Ninan A, Johny K.
    Ther Apher Dial; 2007 Apr; 11(2):101-6. PubMed ID: 17381530
    [Abstract] [Full Text] [Related]

  • 19. Hepatitis B and hepatitis C virus infection and outcome of hemodialysis and kidney transplant patients.
    Lezaic V, Stosovic M, Marinkovic J, Rangelov V, Djukanovic L.
    Ren Fail; 2008 Apr; 30(1):81-7. PubMed ID: 18197548
    [Abstract] [Full Text] [Related]

  • 20. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin.
    Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD.
    Nephrol Dial Transplant; 2006 May; 21(5):1270-7. PubMed ID: 16421163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.